Pricing Log in Create free account

Immatics N.V. (IMTX) vs Janux Therapeutics, Inc. (JANX)

Immatics N.V. and Janux Therapeutics, Inc. are both Biotechnology companies. Immatics N.V. and Janux Therapeutics, Inc. are of similar size ($981.9M and $924.8M). Janux Therapeutics, Inc. grew revenue faster over the last twelve months: 214.4% against −65.0%. Janux Therapeutics, Inc. has the higher net margin (−300.0% vs −489.4%) and the higher return on invested capital (0.00% vs −84.8%). Across the 15 metrics below, Janux Therapeutics, Inc. leads on 13 and Immatics N.V. on 2.

Valuation

Metric IMTX JANX Biotechnology median
P/E n/m n/m 10.60
P/S 17.61 33.41 9.40
P/B 1.87 1.22 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 12.12 5.00 9.02
Earnings yield (29.34%) (9.02%) (32.88%)
Free cash flow yield (27.74%) (4.87%) (23.13%)

Profitability

Metric IMTX JANX Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (536.26%) (419.24%) 0.00%
Net margin (489.35%) (299.95%) 0.00%
Free cash flow margin (488.01%) (162.70%) 0.00%
Return on equity (48.53%) (10.58%) (51.96%)
Return on assets (39.83%) (9.94%) (46.06%)
Return on invested capital (84.83%) 0.00% 0.00%

Growth

Metric IMTX JANX Biotechnology median
Revenue growth (TTM) (64.99%) 214.40% 6.76%
EPS growth (last fiscal year) (1,313.33%) (42.97%) 29.88%
Revenue growth, 5-year CAGR 11.81% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMTX JANX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.54 17.69 4.97
Net debt to EBITDA 2.04 5.58 1.01

Dividend

Metric IMTX JANX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IMTX JANX Biotechnology median
Market cap 924.75m 981.86m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack